Sotera Health Co. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates through three reportable segments: Sterigenics (terminal sterilization), Nordion (Co-60 supply and gamma irradiation systems), and Nelson Labs (microbiological and analytical testing).
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Net Revenues | $311.3 million | $285.5 million | $860.2 million | $810.2 million |
| Gross Profit | $177.6 million | $158.0 million | $479.6 million | $437.9 million |
| Net Income | $48.4 million | $17.0 million | $43.1 million | $32.1 million |
| Diluted EPS | $0.17 | $0.06 | $0.15 | $0.11 |
| Adjusted EBITDA | $164.2 million | $146.4 million | $436.8 million | $395.6 million |
| Operating Cash Flow (9M) | $184.1 million (vs. $168.4 million in 9M 2024) | |||
| Cash & Equivalents | $299.2 million (as of Sept 30, 2025) | |||
| Total Debt (Gross) | $2.173 billion (Term Loan: $1.423B; Senior Notes: $750M) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenues increased 9.1% year-over-year, driven by volume/mix growth in Sterigenics and Nordion, and favorable pricing. Product revenues (Nordion) rose 19.5% due to Co-60 harvest timing.
- Profitability Surge: Net income increased 184.7% in Q3 2025 compared to Q3 2024. This was significantly aided by a reduction in amortization of intangible assets ($3.1M in Q3 2025 vs. $15.5M in Q3 2024) as certain assets were fully amortized in May 2025.
- Interest Expense: Net interest expense decreased 5.8% in Q3 2025 due to a lower weighted average interest rate on the Term Loan (6.91% in 2025 vs. 7.86% in 2024) following debt refinancing.
- Segment Performance:
- Sterigenics: Revenue +9.8%; Segment Income +11.6%.
- Nordion: Revenue +22.4%; Segment Income +19.9%.
- Nelson Labs: Revenue -5.0% (decline in expert advisory services); Segment Income +1.9%.
Guidance, Outlook, Risks, and Unusual Items
- Debt Refinancing: In September 2025, the company executed Amendment No. 6 to its Credit Agreement, repricing Term Loans to reduce the interest rate margin by 0.50% and applying $75.0 million of cash to repay outstanding borrowings. A $1.1 million loss on refinancing was recorded in Q3 2025.
- EO Litigation Settlements: The company settled 97 pending Ethylene Oxide (EO) claims in Illinois for $30.9 million (paid in September 2025) and entered a binding term sheet to settle 129 additional claims for $34.0 million. These settlements are excluded from Adjusted EBITDA.
- Legal Proceedings: Significant ongoing litigation includes EO tort lawsuits in California, Georgia, and New Mexico. In Georgia, the Court of Appeals vacated a Phase 1 ruling on general causation and remanded the case. In Illinois, the company is vigorously defending remaining claims.
- Risk Factors: Key risks include supply chain disruptions for EO and Co-60, geopolitical instability, regulatory changes, and the potential for future EO litigation settlements. The company notes that insurance coverage for EO claims has been fully utilized.
- Outlook: Management expects cash on hand, operating cash flows, and credit facility availability to meet working capital and debt service requirements for the next 12 months. No specific forward-looking financial guidance was provided in this text.
Investor Verification Checklist
- EO Litigation Exposure: Verify the status of the $34.0 million Illinois settlement conditions and the progress of the Georgia Phase 1 appeals and California trials.
- Amortization Run-Rate: Confirm the sustainability of the reduced amortization expense ($3.1M in Q3 2025) now that certain intangible assets are fully amortized.
- Debt Covenants: Review the specific leverage ratios and covenants under the amended Credit Agreement and Senior Notes to ensure compliance given the high debt load ($2.17B).
- Nelson Labs Trend: Investigate the 5.0% revenue decline in Nelson Labs to determine if the drop in expert advisory services is a temporary shift or a structural change.
- Insurance Recovery: Assess the likelihood of recovering defense costs from the $110.2 million judgment against the insurer in the Northern District of Illinois, currently pending before the Illinois Supreme Court.